In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study
Open Access
- 12 January 2012
- journal article
- Published by American Society of Hematology in Blood
- Vol. 119 (2), 355-363
- https://doi.org/10.1182/blood-2011-05-355222
Abstract
We have developed and previously reported on a therapeutic vaccination strategy for indolent B-cell lymphoma that combines local radiation to enhance tumor immunogenicity with the injection into the tumor of a TLR9 agonist. As a result, antitumor CD8+ T cells are induced, and systemic tumor regression was documented. Because the vaccination occurs in situ, there is no need to manufacture a vaccine product. We have now explored this strategy in a second disease: mycosis fungoides (MF). We treated 15 patients. Clinical responses were assessed at the distant, untreated sites as a measure of systemic antitumor activity. Five clinically meaningful responses were observed. The procedure was well tolerated and adverse effects consisted mostly of mild and transient injection site or flu-like symptoms. The immunized sites showed a significant reduction of CD25+, Foxp3+ T cells that could be either MF cells or tissue regulatory T cells and a similar reduction in S100+, CD1a+ dendritic cells. There was a trend toward greater reduction of CD25+ T cells and skin dendritic cells in clinical responders versus nonresponders. Our in situ vaccination strategy is feasible also in MF and the clinical responses that occurred in a subset of patients warrant further study with modifications to augment these therapeutic effects. This study is registered at www.clinicaltrials.gov as NCT00226993.Keywords
This publication has 26 references indexed in Scilit:
- Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of CancerJournal of Clinical Oncology, 2011
- Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphomaJournal of the American Academy of Dermatology, 2010
- In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II StudyJournal of Clinical Oncology, 2010
- Dendritic Cell Vaccination Combined with CTLA4 Blockade in Patients with Metastatic MelanomaClinical Cancer Research, 2009
- Migration of Skin Dendritic Cells in Response to Ionizing Radiation ExposureRadiation Research, 2009
- Dysfunctional DC subsets in RCC patients: Ex vivo correction to yield an effective anti-cancer vaccineMolecular Immunology, 2009
- Mechanisms Involved in Radiation Enhancement of Intratumoral Dendritic Cell TherapyJournal of Immunotherapy, 2008
- IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunityBlood, 2007
- Development of TLR9 agonists for cancer therapyJCI Insight, 2007
- Mechanisms and functional significance of tumour-induced dendritic-cell defectsNature Reviews Immunology, 2004